Literature DB >> 2405400

Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1.

C O Jacob1, S Aiso, S A Michie, H O McDevitt, H Acha-Orbea.   

Abstract

The role of tumor necrosis factor alpha (TNF-alpha) in the pathogenesis of autoimmune diabetes mellitus was tested in the nonobese mouse (NOD) model system. The effects of TNF-alpha were assessed on three levels: (i) insulitis development, (ii) development of overt diabetes, (iii) adoptive transfer of diabetes by splenic lymphocytes. Spontaneous diabetes mellitus was blocked in NOD mice by long-term treatment with recombinant TNF-alpha. Treatment with TNF-alpha caused a significant reduction in the lymphocytic infiltration associated with the destruction of the insulin-producing beta cells. Class II major histocompatibility complex Ia expression by islet cells was not up-regulated by TNF-alpha. Moreover, TNF-alpha was able to suppress the induction of diabetes in adoptive transfer of lymphocytes from diabetic female mice to young nondiabetic male NOD mice. These activities of TNF-alpha were shared by interleukin 1 alpha in this system. These studies have implications for the pathogenesis and therapy of autoimmune diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2405400      PMCID: PMC53391          DOI: 10.1073/pnas.87.3.968

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Interdependence of the radioprotective effects of human recombinant interleukin 1 alpha, tumor necrosis factor alpha, granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony-stimulating factor.

Authors:  R Neta; J J Oppenheim; S D Douches
Journal:  J Immunol       Date:  1988-01-01       Impact factor: 5.422

2.  Induction of interleukin 2 receptor (TAC) by tumor necrosis factor in YT cells.

Authors:  J C Lee; A Truneh; M F Smith; K Y Tsang
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

3.  Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes.

Authors:  J A Shizuru; C Taylor-Edwards; B A Banks; A K Gregory; C G Fathman
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

4.  In vivo administration of IL-1 induces thymic hypoplasia and increased levels of serum corticosterone.

Authors:  P J Morrissey; K Charrier; A Alpert; L Bressler
Journal:  J Immunol       Date:  1988-09-01       Impact factor: 5.422

5.  Ultrastructural studies of time-course and cellular specificity of interleukin-1 mediated islet cytotoxicity.

Authors:  T Mandrup-Poulsen; J Egeberg; J Nerup; K Bendtzen; J H Nielsen; C A Dinarello
Journal:  Acta Pathol Microbiol Immunol Scand C       Date:  1987-04

6.  Tumor necrosis factor-alpha induces increased hydrogen peroxide production and Fc receptor expression, but not increased Ia antigen expression by peritoneal macrophages.

Authors:  M Hoffman; J B Weinberg
Journal:  J Leukoc Biol       Date:  1987-12       Impact factor: 4.962

7.  Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity.

Authors:  T Mandrup-Poulsen; K Bendtzen; C A Dinarello; J Nerup
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

8.  Defective activation of T suppressor cell function in nonobese diabetic mice. Potential relation to cytokine deficiencies.

Authors:  D V Serreze; E H Leiter
Journal:  J Immunol       Date:  1988-06-01       Impact factor: 5.422

9.  Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis.

Authors:  C O Jacob; H O McDevitt
Journal:  Nature       Date:  1988-01-28       Impact factor: 49.962

10.  Class-II and IL2 receptor positive cells in the pancreas of NOD mice.

Authors:  A Signore; A Cooke; P Pozzilli; G Butcher; E Simpson; P C Beverley
Journal:  Diabetologia       Date:  1987-11       Impact factor: 10.122

View more
  94 in total

Review 1.  Immunotherapy of immune-mediated diabetes. Present and future.

Authors:  N Maclaren
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

2.  A defect in bone marrow derived dendritic cell maturation in the nonobesediabetic mouse.

Authors:  J Strid; L Lopes; J Marcinkiewicz; L Petrovska; B Nowak; B M Chain; T Lund
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

Review 3.  Prospects for the prevention and reversal of type 1 diabetes mellitus.

Authors:  Nikolai Petrovsky; Diego Silva; Desmond A Schatz
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity.

Authors:  Xin Chen; Joost J Oppenheim
Journal:  FEBS Lett       Date:  2011-04-15       Impact factor: 4.124

5.  Reversal of established autoimmune diabetes by restoration of endogenous beta cell function.

Authors:  S Ryu; S Kodama; K Ryu; D A Schoenfeld; D L Faustman
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 6.  Keratinocyte-derived tumor necrosis factor and the physiopathology of the skin.

Authors:  P F Piguet
Journal:  Springer Semin Immunopathol       Date:  1992

Review 7.  Role of cytokines in the pathogenesis of autoimmune diabetes mellitus.

Authors:  Alex Rabinovitch; Wilma L Suarez-Pinzon
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

Review 8.  The differentiation of the immune system towards anti-islet autoimmunity. Clinical prospects.

Authors:  C Boitard
Journal:  Diabetologia       Date:  1992-12       Impact factor: 10.122

9.  Novel detection of restriction fragment length polymorphisms in the human major histocompatibility complex.

Authors:  S J Cross; S Tonks; J Trowsdale; R D Campbell
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

10.  Pathogenicity of T helper 2 T-cell clones from T-cell receptor transgenic non-obese diabetic mice is determined by tumour necrosis factor-alpha.

Authors:  Jing He; Kathryn Haskins
Journal:  Immunology       Date:  2007-11-05       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.